Boosting Tirzepatide with Nimacimab

Tirzepatide is the GLP1 Receptor Agonist behind popular brands like Mounjaro and Zepbound – it is the most effective FDA approved GLP1 formulation available today.

Skye Biosciences, on the other hand, is a upcoming pharmaceutical company that's working on a product called Nimacimab – which is meant to be taken along with Tirzepatide, and boosts it's effectiveness.

Who are Skye Biosciences?

Skye Biosciences is a new drug development company based in San Diego – so new it has an incredibly slick website:

Skye Bioscience — Innovative Approach to Drug Development

We are a biopharmaceutical company focused on the development of proprietary cannabinoid derivatives for the treatment of glaucoma and other diseases with significant unmet medical needs. Our innovative approach to drug development combines strong science with the drive to find solutions where the need is the greatest.

Skye Bioscience

Skye focuses primarily on applying life science to their drug development, in particular Obesity. They only have one drug in development right now, and it's Nimacimab:

Want to find out more about Nimacimab and Skye biosciences? The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack: